Evidence map›Paper›PMID 27617307›Full record

ArticleEuropean urology focus2016

PTEN Loss as Determined by Clinical-grade Immunohistochemistry Assay Is Associated with Worse Recurrence-free Survival in Prostate Cancer.

Tamara L Lotan, Wei Wei, Carlos L Morais, Sarah T Hawley, Ladan Fazli, Antonio Hurtado-Coll, Dean Troyer, Jesse K McKenney, Jeffrey Simko, Peter R Carroll and 8 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European urology focus, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 1 pooled it
6.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 1 synthesis or guideline pooled it, 74 citations in OpenAlex.

  1. The impact of PTEN deletion and ERG rearrangement on recurrence after treatment for prostate cancer: a systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2020
    Pooled it
  2. Exploratory Analysis of PTEN Deficiency by Immunohistochemistry from the Phase III CAPItello-291 Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Predicting Prostate Cancer Molecular Subtype With Deep Learning on Histopathologic Images.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2023
    Article
  11. Artificial Intelligence-Based PTEN Loss Assessment as an Early Predictor of Prostate Cancer Metastasis After Surgery: A Multicenter Retrospective Study.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2023
    Article
  12. The Movember Global Action Plan 1 (GAP1): Unique Prostate Cancer Tissue Microarray Resource.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2022
    Article
  13. Article
  14. LMNB1, a potential marker for early prostate cancer progression.American journal of cancer research · 2022
    Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 9 institutions in 1 country.

Tamara L LotanPathology Department, Johns Hopkins School of Medicine, Baltimore, MD, USA; Oncology Department, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Wei WeiMD Anderson Cancer Center, Houston, TX, USA.
Carlos L MoraisPathology Department, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Sarah T HawleyCanary Foundation, Palo Alto, CA, USA.
Ladan FazliVancouver Prostate Centre, Vancouver, BC, Canada.
Antonio Hurtado-CollVancouver Prostate Centre, Vancouver, BC, Canada.
Dean TroyerPathology Department, Eastern Virginia Medical School, Norfolk, VA, USA; Urology Department, Eastern Virginia Medical School, Norfolk, VA, USA.
Jesse K McKenneyPathology Department, Cleveland Clinic, Cleveland, OH, USA.
Jeffrey SimkoPathology Department, University of California-San Francisco, San Francisco, CA, USA; Urology Department, University of California-San Francisco, San Francisco, CA, USA.
Peter R CarrollUrology Department, University of California-San Francisco, San Francisco, CA, USA.
Martin GleaveVancouver Prostate Centre, Vancouver, BC, Canada.
Raymond LanceUrology Department, Eastern Virginia Medical School, Norfolk, VA, USA.
Daniel W LinUrology Department, University of Washington, Seattle, WA, USA.
Peter S NelsonOncology Department, University of Washington, Seattle, WA, USA; Pathology Department, University of Washington, Seattle, WA, USA.
Ian M ThompsonUrology Department, University of Texas Health Science Center, San Antonio, TX, USA.
Lawrence D TruePathology Department, University of California-San Francisco, San Francisco, CA, USA.
Ziding FengMD Anderson Cancer Center, Houston, TX, USA.
James D BrooksUrology Department, Stanford University School of Medicine, Stanford, CA, USA.
University of California, San Francisco · USEastern Virginia Medical School · USJohns Hopkins University · USThe University of Texas MD Anderson Cancer Center · USUniversity of Washington · USCanary Foundation · USCleveland Clinic · USStanford University · USThe University of Texas Health Science Center at San Antonio · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
TRANSGENIC MODELS FOR PROSTATE CANCER AND AUTOIMMUNITYP50CA058236 · NCI · JOHNS HOPKINS UNIVERSITY · PI DENMEADE, SAMUEL R · 1992 to 2020
$43.9M
NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA058236
6 · The paper itself

Abstract

background

objectiveWe tested whether PTEN loss is associated with shorter recurrence-free survival (RFS) in surgically treated PCa patients with known ERG status. DESIGN SETTING AND

participantsA genetically validated, automated PTEN immunohistochemistry (IHC) protocol was used for 1275 primary prostate tumors from the Canary Foundation retrospective PCa tissue microarray cohort to assess homogeneous (in all tumor tissue sampled) or heterogeneous (in a subset of tumor tissue sampled) PTEN loss. ERG status as determined by a genetically validated IHC assay was available for a subset of 938 tumors. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Associations between PTEN and ERG status were assessed using Fisher's exact test. Kaplan-Meier and multivariate weighted Cox proportional models for RFS were constructed. RESULTS AND LIMITATIONS: When compared to intact PTEN, homogeneous (hazard ratio [HR] 1.66,

conclusionsThese data suggest that PTEN is a useful prognostic biomarker and that there is no statistically significant interaction between PTEN and ERG status for RFS. PATIENT SUMMARY: We found that loss of the PTEN tumor suppressor gene in prostate tumors as assessed by tissue staining is correlated with shorter time to prostate cancer recurrence after radical prostatectomy.

Indexed as

BiomarkerERGImmunohistochemistryProstatic carcinomaPTENRadical prostatectomy

Identifiers

PMID27617307
PMCPMC5014432
OpenAlexW2160971263

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.